INDUCTION OF IMMUNE TOLERANCE USING METHOTREXATE Russian patent published in 2018 - IPC A61K31/519 A61P37/06 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular, oncology, and can be used to increase the effectiveness of a therapeutic protein in a subject. For this, the method includes administering to a subject an effective amount of methotrexate, wherein the methotrexate is administered to the individual in an effective amount in one cycle, where one cycle of methotrexate consists of 1 day of administration of methotrexate or 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 consecutive days of taking methotrexate. Methotrexate is administered before, or during, or after administration of the therapeutic protein, where the therapeutic protein is selected from the group consisting of a murine anti-thymoglobulin (mATG) protein, alemtuzumab and human alglucosidase alpha (rhGAA), and where the method inhibits the antibody's response to the therapeutic protein, thereby increasing the efficacy of the therapeutic protein in the subject.

EFFECT: use of this method enables, during treatment with one cycle of methotrexate, to reduce undesirable anti- drug antibody (ADA) responses.

15 cl, 16 ex, 3 tbl, 56 dwg